arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Sensei Biotherapeutics, Inc.

FTH
$31.37 ▼ -1.96 (-5.88%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

Sensei Biotherapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $177.0M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -8.4%
FCF / Share $-2.78
Trailing P/E
Price / Book 4.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-170.24M
↓ -2380.1%
FCF / Share Free cash flow per share
$-2.78
↑ +66.5%
Long-Term Debt Long-term obligations
$567.00K
— 0.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
7
Financial Health
5
Cash Quality
64

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters